[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lisata Therapeutics Inc (LSTA)

Lisata Therapeutics Inc (LSTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Are LSTA, MCHX, CZR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

MCHX : 1.7100 (-4.47%)
LSTA : 3.21 (-1.83%)
CZR : 29.82 (-1.75%)
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to...

LSTA : 3.21 (-1.83%)
Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KALV : 27.00 (+0.04%)
LSTA : 3.21 (-1.83%)
SILA : 30.36 (unch)
THR : 61.14 (-8.49%)
Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , March 9, 2026 /PRNewswire/ -- Ademi LLP is investigating Lisata (NASDAQ: LSTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

LSTA : 3.21 (-1.83%)
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously...

LSTA : 3.21 (-1.83%)
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RAPT : 58.02 (+0.07%)
ALGT : 108.26 (-2.59%)
LSTA : 3.21 (-1.83%)
AVO : 13.50 (+0.37%)
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RAPT : 58.02 (+0.07%)
ALGT : 108.26 (-2.59%)
LSTA : 3.21 (-1.83%)
AVO : 13.50 (+0.37%)
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

RAPT : 58.02 (+0.07%)
LSTA : 3.21 (-1.83%)
PEN : 317.28 (-0.32%)
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA

NEW YORK , Jan. 28, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

NATH : 100.81 (-0.21%)
RAPT : 58.02 (+0.07%)
LSTA : 3.21 (-1.83%)
PEN : 317.28 (-0.32%)
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

LSTA : 3.21 (-1.83%)

Barchart Exclusives

Nike’s Dividend Yield Is Near Record Highs, But That’s Not a Good Enough Reason to Buy NKE Stock
Nike's dividend yield is nearly 3.8%, which is near the record highs we saw last month. That, however, does not make the stock a buy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.